| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 |
| filingDate |
1996-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1999-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H11514968-A |
| titleOfInvention |
Nucleotide and peptide sequences for the treatment of myasthenia |
| abstract |
(57) [Summary]nDisclosed is the use of a nucleotide or peptide for the preparation of a medicament suitable for the treatment or prevention of acquired autoimmune myasthenia. The nucleotide sequence encodes a peptide sequence that recognizes all or part of the amino acid sequence of segment Vβ5.1 of the human T cell receptor and can itself cause the formation of an antibody that forms an immunological complex therewith. A sequence capable of recognizing all or a part of the amino acid sequence of the segment Vβ5.1 and encoding a peptide sequence representing an antibody capable of forming an immunological complex therewith; A sequence capable of encoding an antisense RNA capable of hybridizing with all or a part of the mRNA encoded by the DNA sequence encoding the amino acid sequence of Vβ5.1; or a DNA sequence encoding the amino acid sequence of the segment Vβ5.1. Can hybridize to all or part, or all or part of the mRNA encoded by the DNA sequence It is selected from the column. The peptide sequence recognizes the human T-cell receptor segment Vβ5.1 and can itself cause the formation of antibodies that form an immunological complex therewith, or the T-cell receptor segment Vβ5. The amino acid sequence is selected from those corresponding to an antibody capable of recognizing all or a part of the amino acid sequence and forming an immunological complex therewith. |
| priorityDate |
1995-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |